Samsung said Tuesday it had decided to invest in Phrontline Biopharma, a Chinese biotechnology firm with an antibody-drug conjugate platform and pipeline, through Samsung Life Science Fund. Samsung ...

- Company has initiated Phase 1 study with STRO-004, its potential best-in-class Tissue Factor ADC - - Sutro has selected PTK7 as the target for its initial dual-payload candidate, STRO-227 - - ...

This approval builds on BioDlink's earlier success with Lepu Biopharma's ADC program that achieved 100% first-pass success across technology transfer, Process Performance Qualification (PPQ), and ...

GSK plc (NYSE:GSK) and Syndivia on Monday announced an agreement granting GSK exclusive worldwide rights to develop and commercialize a preclinical ADC for metastatic castration-resistant prostate ...

An EDN Design Idea (DI) presented a discussion of how to increase the resolution of an ADC by adding a non-deterministic, zero-mean, Gaussian noise dither waveform to a signal to be converted; then, ...

the DMA channel is passed into the function and compared to the local adc DMA configuration (data->dma.channel) if the channels match ADC conversion completes normally if the channels do not match the ...

Antibody-drug conjugates (ADCs) are transforming targeted cancer therapy, with innovations in conjugation chemistry and payload-linker technologies driving improvements in efficacy, stability, and ...

Ideaya Biosciences, Inc. is advancing darovasertib in a phase 2/3 trial for HLA-A2-negative metastatic uveal melanoma patients, with mPFS data expected by the end of 2025. Ideaya plans a phase 3 study ...

Georgia Northwestern Technical College (GNTC) and Southern Adventist University have developed an academic and educational partnership for GNTC students to enroll in the online Adult Degree Completion ...

LOUDOUN COUNTY, Va (7News) — Loudoun County Public Schools (LCPS) will be partnering with the Loudoun County Sheriff's Office (LCSO) to provide General Educational Development (GED) preparation ...

Antibody-drug conjugates (ADCs) are a growing class of biotherapeutics that have transformed targeted therapy, especially in oncology. By making use of monoclonal antibodies’ specificity to deliver ...